Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07011810 · ClinicalTrials.gov registry record · Phase 2

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
3
Study locations

NCT07011810 is a Phase 2 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 50 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07011810, a Phase 2 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of donor stem cell transplants. Sclerosis, while not associated with a higher risk of death, can lead to serious disabilities. Usual treatments for cGVHD can be associated with significant side effects and unsatisfactory outcomes. A monoclonal antibody, like axatilimab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Axatilimab blocks a receptor and depletes cells that may be involved in the development of inflammation and fibrosis in cGVHD. Giving axatilimab may improve or prevent worsening of sclerosis related to cGVHD in patients after a donor stem cell transplant.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Questionnaire Administration
  • BIOLOGICAL Axatilimab
  • PROCEDURE Skin Biopsy
  • PROCEDURE Skin Measurement

Study Locations (3)

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-08-06
Est. Completion 2030-02-10
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07011810

The ClinicalTrials.gov registry entry for NCT07011810 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT07011810 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, Washington.

Frequently Asked Questions

What is clinical trial NCT07011810 about?

NCT07011810 is a clinical study titled "Axatilimab for Sclerotic Chronic Graft-versus-Host Disease". This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of donor stem cell tra...

What is the current status of trial NCT07011810?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-08-06. Estimated completion is 2030-02-10.

What conditions does trial NCT07011810 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT07011810?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Axatilimab (BIOLOGICAL), Skin Biopsy (PROCEDURE), Skin Measurement (PROCEDURE).

Who is sponsoring clinical trial NCT07011810?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07011810 being conducted?

This trial has 3 study locations across Florida, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.